Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Dr. Kudo Discusses TACE Plus Sorafenib in HCC

February 15th 2018

Masatoshi Kudo, MD, PhD, Department of Gastroenterology and Hepatology, Kindai University, discusses the randomized phase II trial comparing transarterial chemoradiation (TACE) plus sorafenib (Nexavar) with TACE alone in patients with hepatocellular carcinoma (HCC).

Dr. Bekaii-Saab on the Importance of the ReDOS Study in mCRC

February 14th 2018

Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses the importance of the phase II regorafenib (Stivarga) dose optimization study (ReDOS) in metastatic colorectal cancer (mCRC).

Dr. Morse on Managing Toxicities and Sequencing Agents in mCRC

February 12th 2018

Michael A. Morse, MD, professor, Medicine, Department of Surgery, Duke University School of Medicine, Duke Cancer Institute, discusses factors that should be taken into consideration when sequencing agents in metastatic colorectal cancer.

Dr. Marshall on the Importance of Testing for BRAF Mutations in mCRC

February 12th 2018

John L. Marshall, MD, chief, Division of Hematology/Oncology, Medstar Georgetown University Hospital director, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer, discusses the specificity now required in the treatment of patients with metastatic colorectal cancer (mCRC).

Dr. Jarnagin on the Improvements in Surgery for Patients With mCRC

February 12th 2018

William R. Jarnagin, MD, FACS, chief, Hepatopancreatobiliary Service, Benno C. Schmidt Chair, Surgical Oncology, Memorial Sloan Kettering Cancer Center, discusses the progression of surgery in treating patients with metastatic colorectal cancer.

Dr. Chau on Findings of Ramucirumab Plus Pembrolizumab in Gastric/GEJ Cancer

February 9th 2018

Ian Chau, MD, consultant medical oncologist, Royal Marsden Hospital, discusses finding with the combination of ramucirumab (Cyramza) plus pembrolizumab (Keytruda) in gastric or gastroesophageal (GEJ) cancer.

The Future of Treatment in Hepatocellular Carcinoma

February 9th 2018

Locoregional Approaches in Hepatocellular Carcinoma

February 9th 2018

KEYNOTE-224: Second-Line Pembrolizumab

February 9th 2018

Immunotherapy Approaches in Hepatocellular Carcinoma

February 9th 2018

CELESTIAL Trial: Second-Line Cabozantinib's Value in HCC

February 9th 2018

REFLECT Trial: Frontline Lenvatinib's Value in HCC

February 9th 2018

Hepatocellular Carcinoma: A Changing Treatment Landscape

February 9th 2018

Overman Highlights Latest Nivolumab Results in MSI-H/dMMR mCRC

February 8th 2018

Michael J. Overman, MD, discusses updated findings from the single-agent nivolumab CheckMate-142 cohort and combination data for nivolumab/ipilimumab from the pivotal trial.

Dr. Overman Discusses Immunotherapy and MSI Testing in CRC

February 8th 2018

Michael J. Overman, MD, associate professor, department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses immunotherapy and microsatellite instability (MSI) testing in colorectal caner (CRC).

Alpelisib Active in PIK3CA-Altered Solid Tumors

February 8th 2018

Alpelisib (BYL719) induced a disease control rate of 58.2% and stable disease rate of 52.2% in patients with advanced solid tumors.

CRC: Deciding on Duration of Adjuvant Therapy

February 8th 2018

Antibody Selection and Tumor Sidedness in CRC

February 8th 2018

Implications of Recent Data from CheckMate-142 in CRC

February 8th 2018

Early-Onset Colorectal Cancer: What Do We Know?

February 8th 2018